Which HIV/HCV-coinfected patients should be treated for chronic hepatitis C and how?
• Management of HIV/HCV-coinfected patients with end-stage liver disease Treatment for decompensated liver disease Liver transplantation • Future research questions With highly active antiretroviral therapy (HAART), HIV-infected patients can now live longer and healthier lives, and other comorbid diseases, such as chronic hepatitis C, have emerged as a significant health concern. Coinfection with the hepatitis C virus (HCV) may limit life expectancy because it can lead to serious liver disease including decompensated liver cirrhosis and hepatocellular carcinoma. HCV-induced fibrosis progresses faster in HIV/HCV-coinfected persons, although HAART may be able to decrease this disease acceleration. Combination therapy for HCV with interferon and ribavirin can achieve a sustained viral response, although at a lower rate than in HCV-monoinfected patients. Combination treatment with pegylated interferon and ribavirin will probably emerge as the next HCV therapy of choice for HIV/HCV-coinfect
Related Questions
- Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease?
- Does ascorbic acid prevent retinopathy during interferon therapy in patients with chronic hepatitis C?
- Which HIV/HCV-coinfected patients should be treated for chronic hepatitis C and how?
